In vitro activity of novel gyrase inhibitors against a highly resistant population of pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2887-2889

  Tessier, Pamela R ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GYRASE INHIBITOR; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG ISOLATION; DRUG STRUCTURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84877861234     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01740-12     Document Type: Article

References (10)

1. Eagye KJ, Banevicius MA, Nicolau DP. 2012. Pseudomonas aeruginosa is not just in the intensive care unit any more: Implications for empirical therapy. Crit. Care Med. 40:1329-1332.
2. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
3. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. 2009. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin. Ther. 31:2678-2688.
4. Tari LW, Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Nix J, Finn. 2013. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I. Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. Bioorg. Med. Chem. Lett. 23: 1529-1536.
5. Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Nelson K, Brown-Driver V, Castellano A, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Finn J, Tari LW. 2013. Pyrrolopyrimidine inhibitors ofDNAgyrase B (GyrB) and topoisomerase IV (ParE). Part II. Development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Bioorg. Med. Chem. Lett. 23:1537-1543.
6. Pillar CM, Stapert L, Marchak MA, Shinabarger DL. 2012. Potent activity of novel gyrase/topoisomerase inhibitors against gram-negative and gram-positive pathogens with important resistance phenotypes, poster F-2019. Abstr. 52nd Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 9 to 12 September 2012.
7. Brown-Driver V, Castellano A, Nelson K, Li X, Lam T, Trzoss M, Zhang J, Chen Z, Lee S, Shaw KJ, Finn J. 2012. Advanced microbiological profile of new DNA gyrase/topoisomerase IV inhibitors, poster F-2024. Abstr. 52nd Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 9 to 12 September 2012.
8. Crandon JL, Shuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacy of human simulated exposures of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56: 6137-6146.
9. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eleventh edition. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
10. CLSI. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.